Practical Tips for Caring for Melanoma Patients
|
|
- Sophie Williams
- 5 years ago
- Views:
Transcription
1 Practical Tips for Caring for Melanoma Patients Caroline C. Kim, MD, Director Assistant Professor, Department of Dermatology Harvard Medical School Director, Pigmented Lesion Clinic Associate Director, Cutaneous Oncology Program Beth Israel Deaconess Medical Center, Boston, MA Managing Patients with Melanoma and Other Melanocytic Neoplasms Symposium S027 American Academy of Dermatology Annual Meeting, February 17, :00pm, San Diego, CA
2 Disclosures No relevant conflicts of interest Relationships Hoffmann-La Roche, Ltd. Investigator
3 Role of Dermatologist in Care of Melanoma Patients Before diagnosis 1. Education/Prevention 2. Skin cancer screening, biopsy/diagnosis, wide excisions of thin melanomas After diagnosis 1. Referring for SLNBx/oncology 2. Education/prevention 3. Screening, biopsy/diagnosis, treatment of additional primary melanoma 3. Screening, biopsy/diagnosis, treatment of metastasis/disease progression 4. Coordination with other disciplines for patient care and systemic treatments
4 Clinical Pearls Look for signatures and the ugly duckling!
5 Clinical Pearls Look for signatures and the ugly duckling! Look at the edge of difficult lesions and beware of inflammation
6 Clinical Pearls Look for signatures and the ugly duckling! Look at the edge of difficult lesions and beware of inflammation Your biopsy and closure matters
7 Biopsy Variable types of biopsies performed my.webmd.com
8 2011: American Academy Dermatology and NCCN Guidelines FROM THE ACADEMY Guidelines of care for the management of primary cutaneous melanoma Work Group: Christopher K. Bichakjian, MD, a Allan C. Halpern, MD (Co-chair), b Timothy M. Johnson, MD (Co-chair), a Table IV. Recommendations Antoinette Foote Hood, MD, c for biopsy James M. Grichnik, MD, PhD, d Susan M. Swetter, MD, e,f Hensin Tsao, MD, PhD, g Preferred Victoria Holloway biopsy technique Barbosa, is MD, narrow h Tsu-Yi excisional Chuang, biopsy MD, MPH, that i,j Madeleine Duvic, MD, k Vincent C. Ho, MD, l encompasses Arthur J. Sober, entire MD, breadth g Karl R. ofbeutner, lesion with MD, clinically PhD, m,n Reva Bhushan, PhD, o negative margins and Wendy to depth Smith sufficient Begolka, toms ensure o that Ann Arbor, Michigan; Newlesion York, is New notyork; transected, Norfolk, which Virginia; may be Miami, accomplished Florida; Palo by Alto, Los Angeles, Palm Springs, San Francisco, elliptical and Fairfield, or punch California; excisionboston, with sutures, Massachusetts; or shave Chicago and Schaumburg, Illinois; removal Houston, totexas; depth and belowvancouver, anticipated British planecolumbia, of lesion. Canada Partial sampling (incisional biopsy) is acceptable in select clinical circumstances such as facial or acral location, low clinical suspicion or uncertainty of diagnosis, or very large lesion. Repeat biopsy is recommended if initial biopsy specimen is inadequate for diagnosis or microstaging of primary lesion. NCCN Practice Guidelines in Oncology v Melanoma
9 High suspicion for melanoma: narrow excisional biopsy preferred 1-3 mm margins
10 Partial/incisional biopsy: Facial or acral areas Very large lesions Low suspicion Be aware of limitations of partial / incisional biopsy
11 Think about your biopsy Degree of suspicion for melanoma Possible need for wide local excision and sentinel lymph node biopsy
12
13 Clinical Pearls Look for signatures and the ugly duckling! Look at the edge of difficult lesions and beware of inflammation Your biopsy and closure matters Talk to your pathologist for difficult lesions
14 Talk to your pathologist about difficult lesions *MELTUMP (Melanocytic Tumor of Uncertain Malignant Potential): ask for breslow depth *Regression: ask for assessment of depth
15 Clinical Pearls Look for signatures and the ugly duckling! Look at the edge of difficult lesions and beware of inflammation Your biopsy and closure matters Talk to your pathologist for difficult lesions * MELTUMP, regression Keep up with guidelines: SLNBx and management
16 What melanomas are you referring for a SLNBx currently? 1. I don t refer for SLNBx for my melanoma patients 2. Melanomas >=0.8 mm and thinner tumors with ulceration 3. Melanomas >=0.8 mm and those thinner with ulceration and mitoses 4. Melanomas >=1.0 mm and those thinner with ulceration and mitoses 5. None of the above, I use a different algorithm
17 2009 AJCC Melanoma TNM Classification 7 th edition Classification Thickness (mm) Ulceration Status/Mitoses T Tis NA NA T1 <=1.00 a: Without ulceration <=1.00 b: With ulceration or mitoses >=1/ mm 2 *T1B tumors T a: Without ulceration have ~ 5-10% risk of b: With ulceration occult T a: Without ulceration metastases in SLN b: With ulceration T4 > 4.00 a: Without ulceration b: With ulceration
18 2017 AJCC Melanoma TNM Classification 8 th edition Classification Thickness (mm) Ulceration Status T Tis NA NA T1 <0.8 a: Without ulceration <0.8 mm b: With ulceration b: With or without ulceration T2 > a: Without ulceration b: With ulceration T3 > a: Without ulceration *T1B tumors have ~ 5-10% risk of occult metastases in SLN b: With ulceration T4 > 4.00 a: Without ulceration b: With ulceration
19 Guidelines for consideration of SLNBx AJCC 2017: --Melanomas >= 0.8 mm thick --Melanomas <0.8 mm with ulceration NCCN: -- Melanomas >=0.8 mm -- Melanomas <0.8 mm with ulceration -- Melanomas <0.8 mm with high-risk features such as mitotic rate >2 mits/mm2, lymphovascular invasion AJCC 8 th edition NCCN melanoma guidelines
20 Follow-up for melanoma patients Education and total body skin examination including lymph node examination Frequency of follow-up depends on risk of recurrence --NCCN: Early stages (IA-IIA): every 6-12 mo for 5 years Later stages (stage IIB-IV): every 3-6 mo for 2 years then every 6-12 mo for 3 years MMIS/ melanoma patient: at least annually for life Consideration of total body photography if appropriate
21 Clinical Pearls Look for signatures and the ugly duckling! Look at the edge of difficult lesions and beware of inflammation Your biopsy and closure matters Talk to your pathologist for difficult lesions * MELTUMP, regression Keep up with guidelines: SLNBx and management Second primary melanomas may not look like the first
22 Second primary melanomas Incidence: Range reported in literature: 1.3%-20.4% of all melanoma patients; Relative risk of 2 nd primary melanoma: ~9 fold increased risk compared to population Risk factors: may include: older age, male, fair skinned, fair/blond hair, head/neck primaries, lower-staged disease (Jones et al.) Bradford PT et al. Increased risk of second primary cancers after diagnosis of melanoma. Arch Dermatol Mar; 146(3): Jones M.S. et al. Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. Am Surg 2016 Oct; 82(10):
23 Second primary melanomas Incidence: Range reported in literature: 1.3%-20.4% of all melanoma patients; Relative risk of 2 nd primary melanoma: ~9 fold increased risk compare to population Risk factors: may include: older age, male, fair skinned, fair/blond hair, head/neck primaries, lower-staged disease (Jones et al.) Second primary melanomas likely thinner than 1 st melanoma Prognosis: may be better than those with one melanoma (Jones et al.) Jones M.S. et al. Second Primary Melanoma: Risk Factors, Histopathologic Features, Survival, and Implications for Follow-Up. Am Surg 2016 Oct; 82(10):
24 2 nd primary melanomas: MMIS patients need to be followed Pomerantz H et al. Risk of subsequent melanoma after melanoma in situ and invasive melanoma: a population-based J Am Acad Dermatol 2015 May: 72(5): Cohort study: Patients identified as having melanoma in situ or invasive melanoma as their first cancer in the Surveillance, Epidemiology, and End Results (SEER) program between Melanoma in situ cohort more likely: -- to develop a 2 nd melanoma at any stage after 2 years than invasive melanoma cohort (p<0.001) --to develop subsequent invasive melanoma after 10 years than invasive melanoma cohort (P=0.003) --to develop subsequent melanoma in situ at all time points (p < 0.001)
25 Second primary melanomas Vernali et al. Association of incident amelanotic melanoma with phenotypic characteristics, MC1R status and prior amelanotic melanoma. JAMA Dermatology (published online July 26, 2017). The Genes, Environment, and Melanoma (GEM) study: international cohort of patients from population-based and hospital-based registries ( ). 527 patients with multiple primary melanomas 24 patients with amelanotic melanoma: 20.8% had prior amelanotic melanoma 503 patients with pigmented melanoma: 5.4% had prior amelanotic melanoma Patients with amelanotic melanoma more likely to have a prior amelanotic melanoma (OR 4.62; 95% CI, , p=0.01) However: Second primary melanomas may not look like the first melanoma! Educate patients: continue looking for any ugly ducklings
26 Clinical Pearls Look for signatures and the ugly duckling! Look at the edge of difficult lesions and beware of inflammation Your biopsy and closure matters Talk to your pathologist for difficult lesions * regression Keep up with guidelines: SLNBx and management Second primary melanomas may not look like the first Melanoma recurrences and metastases can be any color
27 In transit metastases Management depends on clinical scenario: One or few: --if feasible, excisional biopsy with clear margins --coordinate with oncologist/surgeon: restaging scans, treatment discusssions Multiple or unresectable: --coordinate with oncologist/surgeon: restaging scans, treatment discussions: Intralesional therapy (i.e. T-VEC), systemic therapy (immunomodulating agents, targeted inhibitors, clinical trials), other (BCG, imiquimod, XRT, limb perfusion) NCCN Guidelines
28 Suspicious subcutaneous nodules or lymphadenopathy Coordinate with oncologist/surgeon Fine needle aspiration or core biopsy, other biopsy type, imaging may be needed
29 Clinical Pearls Look for signatures and the ugly duckling! Look at the edge of difficult lesions and beware of inflammation Your biopsy and closure matters Talk to your pathologist for difficult lesions * MELTUMP, regression Keep up with guidelines: SLNBx and management Second primary melanomas may not look like the first Melanoma recurrences and metastases can be any color Management principles for in transit metastases/nodal disease
30 Summary Dermatologists play an important role in patient care both before and after a melanoma diagnosis Clinical pearls: Look for signatures and the ugly duckling! Look at the edge of difficult lesions and beware of inflammation Your biopsy and closure matters Talk to your pathologist for difficult lesions * MELTUMP, regression Keep up with guidelines: SLNBx and management Second primary melanomas may not look like the first Melanoma recurrences and metastases can be any color Management principles for in transit metastases/nodal
31 Thank you! Caroline C. Kim, MD, Director Assistant Professor, Department of Dermatology Harvard Medical School Director, Pigmented Lesion Clinic Associate Director, Cutaneous Oncology Program Beth Israel Deaconess Medical Center, Boston, MA Managing Patients with Melanoma and Other Melanocytic Neoplasms Symposium S027 American Academy of Dermatology Annual Meeting, February 17, :00pm, San Diego, CA
Practical Management of Atypical Melanocytic Lesions
Practical Management of Atypical Melanocytic Lesions Caroline C. Kim, MD, Director Assistant Professor, Department of Dermatology Harvard Medical School Director, Pigmented Lesion Clinic Associate Director,
More informationPractical Management of Atypical Melanocytic Lesions
Practical Management of Atypical Melanocytic Lesions Caroline C. Kim, MD, Director Assistant Professor, Department of Dermatology Harvard Medical School Director, Pigmented Lesion Clinic Associate Director,
More informationTranslating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy
American Academy of Dermatology 2018 Annual Meeting San Diego, CA, February 17, 2018 Translating Evidence into Practice: Primary Cutaneous Melanoma Guidelines. Sentinel Lymph Node Biopsy Christopher Bichakjian,
More informationDr. Brent Doolan, BSc MBBS MPH
Impact of partial biopsies on the need for complete excisional surgery in the management of cutaneous melanomas: A multi-centre review Dr. Brent Doolan, BSc MBBS MPH Peter MacCallum Cancer Centre, Melbourne
More informationToby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma
Distinguishing Pigmented Skin Lesions and Melanoma Toby Maurer, MD University of California, San Francisco Epidemiology of Melanoma Lifetime risk of an American developing melanoma 1935: 1 in 1500 1980:
More informationToby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma
Distinguishing Pigmented Skin Lesions and Melanoma Toby Maurer, MD University of California, San Francisco Epidemiology of Melanoma Lifetime risk of an American developing melanoma 1935: 1 in 1500 1980:
More informationMelanoma and Dermoscopy. Disclosure Statement: ABCDE's of melanoma. Co-President, Usatine Media
Melanoma and Dermoscopy Richard P. Usatine, MD, FAAFP Professor, Family and Community Medicine Professor, Dermatology and Cutaneous Surgery Medical Director, University Skin Clinic University of Texas
More informationYou Are Going to Cut How Much Skin? Locoregional Surgical Treatment. Justin Rivard MD, MSc, FRCSC September 21, 2018
You Are Going to Cut How Much Skin? Locoregional Surgical Treatment Justin Rivard MD, MSc, FRCSC September 21, 2018 Presenter Disclosure Faculty/Speaker: Justin Rivard Relationships with financial sponsors:
More informationWhat are the new AJCC Staging System changes, and how will they affect my patients?
What are the new AJCC Staging System changes, and how will they affect my patients? Emily Y. Chu, M.D., Ph.D. Assistant Professor of Dermatology & Pathology and Laboratory Medicine University of Pennsylvania
More informationCutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)
The Sentinel Node in Head and Neck Melanoma Cutaneous Melanoma: Epidemiology (USA) 6 th leading cause of cancer among men and women 68,720 new cases of invasive melanoma in 2009 8,650 deaths from melanoma
More informationTalk to Your Doctor. Fact Sheet
Talk to Your Doctor Hearing the words you have skin cancer is overwhelming and would leave anyone with a lot of questions. If you have been diagnosed with Stage I or II cutaneous melanoma with no apparent
More informationUpdates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD
Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD Disclosure Statement Update on Melanoma Are You Following the Latest Guidelines of Care? I, Jerry D. Brewer, MD, do
More informationMelanoma Update: 8th Edition of AJCC Staging System
Melanoma Update: 8th Edition of AJCC Staging System Rosalie Elenitsas, M.D. Professor of Dermatology Director, Dermatopathology University of Pennsylvania DISCLOSURE OF RELATIONSHIPS WITH INDUSTRY None
More informationManagement of Atypical Pigmented Lesions
Management of Atypical Pigmented Lesions Jennifer A. Stein MD, PhD Associate Director, Pigmented Lesion Section Ronald O. Perelman Department of Dermatology NYU Langone Medical Center July 29, 2017 1-4
More informationPrimary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type
Primary Cutaneous Melanoma Pathology Reporting Proforma Includes the International Collaboration on Cancer reporting dataset denoted by * Family name Given name(s) Date of birth DD MM YYYY Sex Male Female
More informationCase Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors
CASE SCENARIO 1 9/10/13 HISTORY: Patient is a 67-year-old white male and presents with lesion located 4-5cm above his right ear. The lesion has been present for years. No lymphadenopathy. 9/10/13 anterior
More informationAdvances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision
Advances in Surgical Management of Primary Melanoma: Identifying Patients Who Need More than Conventional Wide Local Excision Christopher J. Miller, MD Director of Penn Dermatology Oncology Center Associate
More informationWork-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients
2018 AAD Annual Meeting, San Diego, CA Work-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion
More informationWhen Do I Consider Myself Cured?
The Melanoma Patient Symposium - Science to Survivorship When Do I Consider Myself Cured? 26 September 2009 Jeffrey E. Gershenwald, MD, FACS Professor of Surgery, Dept. of Surgical Oncology Professor,
More informationAJCC 8 Implementation January 1, 2018 Melanoma of the Skin. Suraj Venna
AJCC 8 Implementation January 1, 2018 Melanoma of the Skin Suraj Venna Personalized Medicine AJCC 8 th Edition This Time It s Personal Traditional AJCC (TNM) population-based analyses of large databases
More informationDisclosures. SLNB for Melanoma 25/02/2014 SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION
8 th Canadian Melanoma Conference February 22, 2014 Rimrock Resort Hotel, Banff, Alberta SENTINEL LYMPH NODE BIOPSY FOR MELANOMA: CURRENT GUIDELINES AND THEIR CLINICAL APPLICATION Christopher Bichakjian,
More informationContrast with Australian Guidelines A/Pr Pascale Guitera,
Contrast with Australian Guidelines A/Pr Pascale Guitera, Dermatologist, Sydney University NO CONFLICT OF INTEREST Sydney Melanoma Diagnostic Centre, RPAH 2011 2008 225 pages 16 pages http://www.cancer.org.au/file/healthprofessionals/clinica
More informationNAACCR Webinar Series 1
Collecting Cancer Data: Melanoma 2013 2014 NAACCR Webinar Series April 3, 2014 Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationWHAT DOES THE PATHOLOGY REPORT MEAN?
Melanoma WHAT IS MELANOMA? Melanoma is a type of cancer that affects cells called melanocytes. These cells are found mainly in skin but also in the lining of other areas such as nose and rectum, and also
More informationGenetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology
Genetic Testing: When should it be ordered? Julie Schloemer, MD Dermatology Outline Germline testing CDKN2A BRCA2 BAP1 Somatic testing Gene expression profiling (GEP) BRAF Germline vs Somatic testing
More information47. Melanoma of the Skin
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationIdentifying Skin Cancer. Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018
Identifying Skin Cancer Mary S. Stone MD Professor of Dermatology and Pathology University of Iowa Carver College of Medicine March, 2018 American Cancer Society web site Skin Cancer Melanoma Non-Melanoma
More informationAcral and Mucosal Dermoscopy
Acral and Mucosal Dermoscopy Caroline C. Kim, MD Assistant Professor, Department of Dermatology Harvard Medical School Director, Pigmented Lesion Clinic Associate Director, Cutaneous Oncology Program Beth
More informationMelanoma Surgery Update James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division
Melanoma Surgery Update 2018 James R. Ouellette, DO FACS Premier Health Cancer Institute Wright State University Chief, Surgical Oncology Division Surgery for Melanoma Mainstay of treatment for potentially
More informationSKIN CANCER. Most common cancer diagnosis 40% of all cancers
SKIN CANCER Most common cancer diagnosis 40% of all cancers OBJECTIVES Review common and uncommon cancers of the skin. Special emphasis on melanoma and dysplastic nevus Review pathology/tnm/staging, which
More informationProtocol applies to melanoma of cutaneous surfaces only.
Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC
More informationControversies and Questions in the Surgical Treatment of Melanoma
Controversies and Questions in the Surgical Treatment of Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Division of Endocrine and Oncologic Surgery University of Pennsylvania School
More informationPrinted by Martina Huckova on 10/3/2011 3:04:54 PM. For personal use only. Not approved for distribution. Copyright 2011 National Comprehensive
Table of Contents NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level
More informationSkin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012
Skin Malignancies Non - Melanoma & Melanoma Marilyn Ng, MD Dept. of Surgery M&M Conference Downstate Medical Center July 19, 2012 Case Presentation 57 yo man with 3 month hx of a nonhealing < 1 cm right
More informationMelanoma: The Basics. What is a melanocyte?
Melanoma: The Basics What is a melanocyte? A melanocyte is a normal cell, found in the skin, which produces melanin. Melanin is a black or dark brown pigment that is seen in the skin, hair, and parts of
More informationPoor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment
Poor prognosis for thin ulcerated melanomas and implications for a more aggressive approach to treatment Makenzie L. Hawkins, MSPH 1 Matthew J. Rioth, MD 1,2 Megan M. Eguchi, MPH 1 Myles Cockburn, Phd
More informationMelanoma. Kaushik Mukherjee MD A. Scott Pearson MD
Melanoma Kaushik Mukherjee MD A. Scott Pearson MD Disclosures You still have to study Not all inclusive No Western blots Extensive use of Google Image Search and Sabiston Melanoma Basics 8 th most common
More informationWorld Articles of Ear, Nose and Throat Page 1
World Articles of Ear, Nose and Throat ---------------------Page 1 Primary Malignant Melanoma of the Tongue: A Case Report Authors: Nanayakkara PR*, Arudchelvam JD** Ariyaratne JC*, Mendis K*, Jayasekera
More informationCorporate Medical Policy
Corporate Medical Policy Gene Expression Profiling for Cutaneous Melanoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gene_expression_profiling_for_cutaneous_melanoma 5/2018
More informationMelanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective
Melanoma Patients and the Sentinel Lymph Node (SLN) Procedure: An Oncologic Surgeon s Perspective Giorgos C. Karakousis, M.D. Associate Professor of Surgery Hospital of the University of Pennsylvania Disclosures
More informationSkin lesions suspicious for melanoma: New Zealand excision margin guidelines in practice
Skin lesions suspicious for melanoma: excision margin guidelines in practice Tess Brian MBBS; 1 Michael B. Jameson MBChB, FRACP, FRCP, PhD 2,3 1 Department of Plastic and Reconstructive Surgery, Waikato
More informationVernon K. Sondak. Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida
Vernon K. Sondak Department of Cutaneous Oncology Moffitt Cancer Center Tampa, Florida Australasian Melanoma Conference 2016 Sydney, NSW, Australia October 29, 2016 Disclosures Dr. Sondak is a compensated
More informationPrecision Surgery for Melanoma
Precision Surgery for Melanoma Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background 87,110 cases of melanoma estimated in
More informationSurgery for Melanoma and What s on the Horizon
and What s on the Horizon Giorgos C. Karakousis, M.D. Assistant Professor of Surgery Perelman School of Medicine at the University of Pennsylvania Background/Overview 76,870 cases of melanoma estimated
More informationUC Davis Dermatology Online Journal
UC Davis Dermatology Online Journal Title Compliance with follow-up among patients with melanoma and non-melanoma skin cancers Permalink https://escholarship.org/uc/item/135583j2 Journal Dermatology Online
More informationMelanoma Quality Reporting
Melanoma Quality Reporting September 1, 2013 December 31, 2016 Laurence McCahill, MD Surgical Oncologist Metro Health Surgical Oncology Metro Health Professional Building 2122 Health Drive SW Wyoming,
More informationMelanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU
Melanoma Underwriting Presented at 2018 AHOU Conference Hank George FALU MELANOMA EPIDEMIOLOGY 70-80,000 American cases annually Majority are in situ or thin > 20% are diagnosed age 45 8-9,000 melanoma
More informationSkin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1
Skin Cancer AMERICAN OSTEOPATHIC COLLEGE OF OCCUPATIONAL & PREVENTIVE MEDICINE OMED 2012 October 8, 2012 E. Robert Wanat II, D.O., M.P.H. Learning Objectives: Identify the 3 Basic Types of Skin Cancer
More informationDr Rosalie Stephens. Mr Richard Martin. Medical Oncologist Auckland City Hospital Auckland
Dr Rosalie Stephens Medical Oncologist Auckland City Hospital Auckland Mr Richard Martin General Surgeon Melanoma Unit Team Waitemata District Health Board Auckland 8:30-9:25 WS #99: Interactive Case Studies
More informationSTAGE CATEGORY DEFINITIONS
CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery TX Tis Tis (DCIS) Tis (LCIS) Tis (Paget s) T1 T1mi T1a T1b T1c a b c
More informationA PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL
A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL OBJECTIVES Discuss current trends and changing concepts in our understanding of
More informationUpdate on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD
Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma Michael T. Tetzlaff MD, PhD Associate Professor Departments of Pathology (Dermatopathology) and Translational and Molecular Pathology
More informationThis is a repository copy of Easily missed? Amelanotic melanoma. White Rose Research Online URL for this paper:
This is a repository copy of Easily missed? Amelanotic melanoma. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/127789/ Version: Accepted Version Article: Muinonen-Martin,
More informationSurgical Issues in Melanoma
Surgical Issues in Melanoma Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Director, Surgical Oncology Training Program Professor of Surgery John Wayne Cancer Institute Surgical
More informationThe Pathology of Neoplasia Part II
The Pathology of Neoplasia Part II February 2018 PAUL BOGNER, MD A S S O C I A T E P R O F E S S O R O F O N C O L O G Y P A T H O L O G Y A N D D E R M A T O L O G Y Clinical goals of cancer pathology
More informationChallenges in Melanoma Diagnosis and Management
Challenges in Melanoma Diagnosis and Management Winter Clinical Dermatology Conference - Hawaii Darrell S. Rigel, MD MS Clinical Professor of Dermatology New York University Medical Center DISCLOSURE OF
More informationQuality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Quality ID #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2018 OPTIONS FOR INDIVIDUAL MEASURES: CLAIMS ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology
More informationMelanoma and Mimickers
Melanoma and Mimickers Kara Walton, MD Assistant Professor of Dermatology and Dermatopathology Medical College of Wisconsin Disclosures No relevant financial disclosures 1 Objectives Recognize common benign
More informationProfessor Michael Eccles
Professor Michael Eccles Developmental Genetics & Pathology Laboratory Pathology Department University of Otago Dunedin 15:00-15:15 Melanoma Metastasis and Treatment Resistance Melanoma metastasis and
More informationTHE ROLE OF CONTEMPORARY IMAGING AND HYBRID METHODS IN THE DIAGNOSIS OF CUTANEOUS MALIGNANT MELANOMA(CMM) AND MERKEL CELL CARCINOMA (MCC)
THE ROLE OF CONTEMPORARY IMAGING AND HYBRID METHODS IN THE DIAGNOSIS OF CUTANEOUS MALIGNANT MELANOMA(CMM) AND MERKEL CELL CARCINOMA (MCC) I.Kostadinova, Sofia, Bulgaria CMM some clinical facts The incidence
More informationSurgical Oncology Perspective of Melanoma
Surgical Oncology Perspective of Melanoma Hans F. Schoellhammer, MD, FACS Assistant Clinical Professor Division of Surgical Oncology September 20, 2018 Nothing to disclose DISCLOSURE Discussion Objectives
More informationDermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.
Squamous cell carcinoma (SCC): A common malignant tumor of keratinocytes arising in the epidermis, usually from a precancerous condition: 1- UV induced actinic keratosis, usually of low grade malignancy.
More informationSpringer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone
Concise Reference Staging and Diagnosing Cutaneous Melanoma Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone Extracted from Handbook of Cutaneous Melanoma: A Guide to Diagnosis and Treatment Published
More informationMeasure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination
Measure #397: Melanoma Reporting National Quality Strategy Domain: Communication and Care Coordination 2017 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Outcome DESCRIPTION: Pathology reports
More informationSeventh Edition Staging 2017 Melanoma. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.
Seventh Edition Staging 2017 Melanoma Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express written
More information> 6000 Mutations in Melanoma. Tests That Cay Be Employed. FISH for Additions/Deletions. Comparative Genomic Hybridization
Winter Clinical 2017: The Assessment and Diagnosis of Melanoma Whitney A. High, MD, JD, MEng Associate Professor, Dermatology & Pathology Director of Dermatopathology (Dermatology) University of Colorado
More informationImpact of Prognostic Factors
Melanoma Prognostic Factors: where we started, where are we going? Impact of Prognostic Factors Staging Management Surgical intervention Adjuvant treatment Suraj Venna, MD Assistant Clinical Professor,
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Melanoma
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 4.2014 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients Continue Version 4.2014, 04/22/14 National Comprehensive
More informationBenign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc
1 Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc Benign lesions Seborrheic Keratoses: Warty, stuck-on Genetics and birthdays Can start in late
More informationDermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial
Dermatology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI Memorial Cutaneous Oncology for the PCP Deanna G. Brown, MD, FAAD Susong Dermatology Consulting Staff at CHI
More informationCollaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]
CS Tumor Size Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ] Note: the specific tumor size as documented in the medical record. If the ONLY information regarding tumor size is the physician's
More informationCutaneous Malignancies: A Primer COPYRIGHT. Marissa Heller, M.D.
Cutaneous Malignancies: A Primer Marissa Heller, M.D. Associate Director of Dermatologic Surgery Department of Dermatology Beth Israel Deaconess Medical Center December 10, 2016 Skin Cancer Non-melanoma
More informationPublished Ahead of Print on December 14, 2009 as /JCO J Clin Oncol by American Society of Clinical Oncology
Published Ahead of Print on December 14, 2009 as 10.1200/JCO.2009.24.7734 The latest version is at http://jco.ascopubs.org/cgi/doi/10.1200/jco.2009.24.7734 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L
More informationMichael T. Tetzlaff MD, PhD
Update on American Joint Cancer Committee (AJCC) staging system for primary cutaneous melanoma Emphasis on concise and accurate reporting of primary and metastatic melanoma for effective risk stratification
More information46. Merkel Cell Carcinoma
1 Terms of Use The cancer staging form is a specific document in the patient record; it is not a substitute for documentation of history, physical examination, and staging evaluation, or for documenting
More informationDesmoplastic Melanoma: Surgical Management and Adjuvant Therapy
Desmoplastic Melanoma: Surgical Management and Adjuvant Therapy Dale Han, MD Assistant Professor Department of Surgery Section of Surgical Oncology No disclosures Background Desmoplastic melanoma (DM)
More informationMalignant Melanoma Introduction increasing incidence increasing mortality skin >50% normal skin pigmented lesion
1 Malignant Melanoma Introduction Melanoma is a malignant tumor of melanocytes, cells that are derived from the neural crest. There is an increasing incidence of melanoma, as well as an increasing mortality,
More informationRebecca Vogel, PGY-4 March 5, 2012
Rebecca Vogel, PGY-4 March 5, 2012 Historical Perspective Changes In The Staging System Studies That Started The Talk Where We Go From Here Cutaneous melanoma has become an increasingly growing problem,
More informationJohan Lyth, J Hansson, C Ingvar, E Mansson-Brahme, P Naredi, U Stierner, G Wagenius and C Lindholm. Linköping University Post Print
Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark s level of invasion: results of a population-based study from the Swedish Melanoma Register Johan
More informationDescriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma
S5.01 The tumour stage and stage grouping must be recorded to the extent possible, based on the AJCC Cancer Staging Manual (7 th Edition). 11 (See Tables S5.01a and S5.01b below.) Table S5.01a AJCC breast
More informationProposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL
Proposal for a 2-stage RCT in high risk primary SCC: COMMISSAR Catherine Harwood Barts Health NHS Trust / QMUL on behalf of Dr Louise Lansbury, Prof Fiona Bath-Hextall Nottingham Centre for Evidence Based
More informationPredictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma
ORIGINAL RESEARCH SURGERY // ANATOMO-PATHOLOGY Predictive Factors for the Positivity of the Sentinel Lymph Node in Malignant Melanoma Călin Crăciun, Orsolya Hankó- Bauer, Zalán Benedek, Sorin Sorlea, Marius
More informationDavid B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma
Common Medicolegal Situations: Misdiagnosis of Melanoma David B. Troxel, MD Medical Director, The Doctors Company, Napa, California Clinical Professor Emeritus, University of California at Berkeley Past
More informationNEW SURGICAL APPROACHES TO MELANOMA THERAPY
NEW SURGICAL APPROACHES TO MELANOMA THERAPY Melanoma 2003: New Insights Into Therapy & Treatment Douglas L. Fraker, M.D. University of Pennsylvania Surgical Treatment of Melanoma Primary resection margins
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Malignant melanoma: assessment and management of malignant melanoma 1.1 Short title Malignant Melanoma 2 The remit The Department
More informationMelanoma of the Skin INTRODUCTION SUMMARY OF CHANGES
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44.6 Skin of upper limb
More informationProfessor Peter Soyer. Academic Dermatologist Brisbane, Australia
Professor Peter Soyer Academic Dermatologist Brisbane, Australia What s New in Melanoma Dermatology Research Centre, The University of Queensland, School of Medicine, Translational Research Institute &
More informationNPQR Quality Payment Program (QPP) Measures 21_18247_LS.
NPQR Quality Payment Program (QPP) Measures 21_18247_LS MEASURE ID: QPP 99 MEASURE TITLE: Breast Cancer Resection Pathology Reporting pt Category (Primary Tumor) and pn Category (Regional Lymph Nodes)
More informationMelanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG
Melanoma-Back to Basics I Thought I Knew Ya! Paul K. Shitabata, M.D. Dermatopathologist APMG At tumor board, a surgeon insists that all level II melanomas are invasive since they have broken through the
More informationClinical Practice Guidelines
Clinical Practice Guidelines Clinical Practice Guidelines for Melanoma Douglas Reintgen, MD, et al H. Lee Moffitt Cancer Center & Research Institute These clinical practice guidelines for melanoma have
More informationMalignant Melanoma Early Stage. A guide for patients
This melanoma patient brochure is designed to help educate melanoma patients and their caregivers. It was developed under the guidance of Dr. Michael Smylie, Professor, Department of Oncology, University
More informationNodal Treatment in Melanoma: Snow to MSLT-II
Nodal Treatment in Melanoma: Snow to MSLT-II Mark B. Faries, MD, FACS Director, Donald L. Morton Melanoma Research Program Program Director, JWCI Complex General Surgical Oncology Fellowship Director,
More informationKnow who is at risk: LOOK! for ABCDs, rapidly changing lesions, do a biopsy when indicated
Lindy P. Fox, MD Assistant Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Applies to adults without history of malignancy or premalignant
More informationClinical Pathological Conference. Malignant Melanoma of the Vulva
Clinical Pathological Conference Malignant Melanoma of the Vulva History F/48 Chinese Married Para 1 Presented in September 2004 Vulval mass for 2 months Associated with watery and blood stained discharge
More informationMELANOMA: HANDS-ON OR HANDS-OFF?
MELANOMA: HANDS-ON OR HANDS-OFF? M SCHAMM MBChB (Pret), FCS (SA) Endocrine and Transplant Surgeon, Department of Surgery, University of the Witwatersrand; and Clinical Head Transplant Surgery, Charlotte
More informationMelanoma of the Skin
24 Melanoma of the Skin C44.0 Skin of lip, NOS C44.1 Eyelid C44.2 External ear C44.3 Skin of other and unspecified parts of face C44.4 Skin of scalp and neck C44.5 Skin of trunk C44. Skin of upper limb
More information1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.
Skin Cancer follow up guidelines If NEW serious diagnosis given: 1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter. 2. Free prescription information details. 3.
More informationInteresting Case Series. Aggressive Tumor of the Midface
Interesting Case Series Aggressive Tumor of the Midface Adrian Frunza, MD, Dragos Slavescu, MD, and Ioan Lascar, MD, PhD Bucharest Emergency Clinical Hospital, Bucharest University School of Medicine,
More informationMelanoma Case Scenario 1
Melanoma Case Scenario 1 History and physical 11/5/16 Patient is a single, 48-year-old male in good health who presented to his primary physician for a yearly physical exam during which a 3.4 x 2.8 x 1.5
More information